Roberto Bernardo, MD
Critical Care Medicine · Stanford, CANPI 1063853109
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Merck at 50.0% of the total. 2025 is the largest year on record at $46,827, more than ten times the $1,316 reported in 2019. Among critical care medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $375.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$49K
- Actelion Pharmaceuticals US, Inc.$29K
- United Therapeutics Corporation$18K
- Bayer$269
- AstraZeneca$194
- GSK$187
- plus $749 from 14 others
Across 38 payments — averaging $12,682 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$260K
- United Therapeutics Corporation$222K
What the payments were for
- Consulting fees$45,11646%
- Speaking & faculty fees$17,07518%
- Travel & lodging$26,05727%
- Food & beverage$8,2438%
- Education$6601%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 81 | $48,584 |
| Actelion Pharmaceuticals US, Inc. | 37 | $28,833 |
| United Therapeutics Corporation | 87 | $18,334 |
| Bayer | 5 | $269 |
| AstraZeneca | 7 | $194 |
| GSK | 13 | $187 |
| AbbVie | 7 | $170 |
| Gilead | 6 | $131 |
| Mentor Worldwide LLC | 1 | $114 |
| Sandoz | 2 | $68 |
| Boehringer Ingelheim | 3 | $58 |
| EKOS Corporation | 1 | $37 |
| Portola Pharmaceuticals, LLC | 1 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Novo Nordisk | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Insmed, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$97,150 in reported general payments places this provider in the 95th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WinrevairSotatercept-Csrk | 65 | $1,222,768 |
| OpsumitMacitentan | 54 | $692,307 |
| Orenitram ErTreprostinil Diolamine | 75 | $529,024 |
| AdempasRiociguat | 23 | $316,167 |
| JardianceEmpagliflozin | 55 | $51,658 |
| OzempicSemaglutide | 14 | $16,102 |
| Sildenafil Citrate | 38 | $3,553 |
| Spironolactone | 39 | $520 |
| Torsemide | 15 | $393 |
| Potassium Chloride | 14 | $296 |
| Gabapentin | 11 | $198 |
| Carvedilol | 15 | $192 |
| Furosemide | 11 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckWinrevair | $48,584 | $1,222,76865 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $28,833 | $692,30754 claims |
| BayerAdempas | $269 | $316,16723 claims |
| Boehringer IngelheimJardiance | $58 | $51,65855 claims |
| Novo NordiskOzempic | $22 | $16,10214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Stanford
- Vanessa MollStanford$106K
- Roger MeccaStanford$40K
- Harmeet BediStanford$40K
- Carlos BrunStanford$17K
- Stephen RuossStanford$14K
- Michelle CaoStanford$10K
- Cedric Franklin RutlandRiverside$3.2M
- Chinh PhanSacramento$467K
- Timothy AlbertsonSacramento$418K
- Stephen ChenMonterey Park$394K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.